GlassScriptPhysician profile
Rambabu Chalasani
NPI 1407845399
$8,128.27
in general payments reported to CMS, 2019-2025
40 companies · $2,735 in 2025
The $2,735 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $452 · 2021: $14.70 · 2023: $1,575 · 2024: $2,954 · 2025: $2,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,228 · Education: $35.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,228.28 |
| Education | $35.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,497.36 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $645.19 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $550.08 | 2023-2025 | Stelara, Tremfya, Remicade |
| Qol Medical, LLC | $525.80 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $272.82 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $243.85 | 2020-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $238.20 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $229.96 | 2023 | Stelara, Remicade, Tremfya |
| Ipsen Biopharmaceuticals, INC | $225.09 | 2025 | Iqirvo |
| Romark Laboratories, Lc | $188.67 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $184.62 | 2024-2025 | |
| Lilly USA, LLC | $182.95 | 2024-2025 | Omvoh |
| Medtronic, INC. | $163.88 | 2025 | Pillcam |
| Aimmune Therapeutics, INC. | $161.27 | 2024-2025 | Vowst, Zenpep |
| Madrigal Pharmaceuticals | $154.17 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $138.05 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $135.92 | 2023-2024 | Dificid, Zinplava |
| E.R. Squibb & Sons, L.L.C. | $118.90 | 2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $113.82 | 2020-2025 | Rebyota |
| Capsovision, INC. | $112.22 | 2024 | Capsocam Plus |
| Regeneron Healthcare Solutions, INC. | $108.74 | 2024-2025 | Dupixent |
| Boston Scientific Corporation | $104.25 | 2024 | Alliance II, Resolution 360 Ultra Clip |
| Redhill Biopharma INC. | $103.88 | 2020 | |
| Celgene Corporation | $102.96 | 2021-2024 | Zeposia |
| Genzyme Corporation | $100.80 | 2024-2025 | |
| Evoke Pharma, INC. | $85.59 | 2023-2025 | Gimoti |
| Braintree Laboratories, INC. | $68.97 | 2020-2025 | Suflave, Sutab |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.57 | 2023 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $57.17 | 2023-2024 | Linzess |
| Celltrion USA INC. | $54.66 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Alnylam Pharmaceuticals INC. | $38.72 | 2025 | Givlaari |
| Mallinckrodt Hospital Products INC. | $26.82 | 2025 | Terlivaz |
| Daiichi Sankyo INC. | $21.42 | 2019 | |
| Exact Sciences Corporation | $18.46 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $16.33 | 2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $16.25 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.39 | 2023 | |
| Ucb, INC. | $14.73 | 2020 | |
| Shire North American Group INC | $13.99 | 2019 | |
| Vivus LLC | $13.75 | 2025 | Pancreaze |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rambabu Chalasani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.